Product Images Sildenafil

This is a table that outlines drug interactions with Sildenafil. For each drug, it specifies whether a dose adjustment is required for changes in the area under the curve (AUC) and maximum concentration (Cmax) of the drug when administered alongside Sildenafil. The fold change and 90% confidence interval (CI) recommendation for each drug is also included. The table includes drugs such as Atorvastatin, Azithromycin, Bosentan, Cimetidine, Erythromycin, and Saquinavir among others. There is also a graph included showing the change relative to Sildenafil alone, with a vertical solid line at x=1.*

This appears to be a list of drugs and their interactions with Acenocoumarol, a medication used to prevent blood clots. The list includes Atorvastatin, Aspirin, Bosentan, and several other drugs. The table provides information on certain values such as INR, AUC, Cmax, and BT. The table also mentions the fold change and 90% CI. The dosage adjustment recommendation for each drug is given as either no adjustment needed or co-administration not recommended. There is a note stating that the addition of Sildenafil to Bosentan therapy may not be helpful in increasing exercise capacity. The text seems to be a summary of results from a study on the effects of drug interactions with Acenocoumarol.*

This appears to be a table or a graph with some numbers and medication names. It seems to be comparing the effectiveness of three drugs (EHildenaflil 1mg TID, Sildenafil Smg TID, and Eildenalil 20mg TID) over a period of 12 weeks. The "change from baseline" is measured in meters, but without more context, it's unclear what this refers to. The plot shows the mean change from baseline and standard error for each treatment at each visit up to week 12.*

NDC 50436-0776-3 is a prescription drug named Sildenafil. It contains 20mg of the active ingredient and is available only with a prescription. The medication is delivered in single-dose packaging, with each pouch containing one tablet. There are approximately 850 pouches in each case. There's accompanying prescribing information to be followed. The remaining text is not understandable and appears to be a company name and address.*